Tevogen Bio And Semper Paratus Acquisition Corporation Announced That The SEC Declared Effective Registration Statement For Business Combination
Portfolio Pulse from Benzinga Newsdesk
Tevogen Bio and Semper Paratus Acquisition Corporation have announced the effectiveness of their registration statement by the SEC for their business combination. The pro forma equity value of Tevogen Bio's portion is expected to be $1.2 billion. Tevogen Bio is a biotech company specializing in T cell therapeutics for virology, oncology, and neurology.
January 05, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Semper Paratus Acquisition Corporation, trading under the ticker LGST, has had its registration statement for a business combination with Tevogen Bio declared effective by the SEC, indicating progress in the merger process.
The effectiveness of the registration statement is a positive regulatory milestone for the merger between Semper Paratus Acquisition Corporation and Tevogen Bio. This news is likely to be viewed favorably by investors as it indicates a significant step towards the completion of the business combination. The expected pro forma equity value of $1.2 billion for Tevogen Bio's portion of the combined company may also lead to positive sentiment among investors, potentially driving up the stock price of LGST in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100